Bringing added convenience to blood glucose monitoring in smartphone-connected device.

Flat insulin allows for flexible dosing with lower likelihood of hypoglycemia. How is it priced vs. Levemir?

Plus, a first look at the Google/Dexcom bandage-like CGM and the smart new Clarity software.

Further evidence underlying the exceedingly crucial need for more pilots in obesity.

Praluent now approved for two specific patient populations. How this drug has the future potential to make a big impact on people with diabetes.

Enrolling now – how this implanted CGM compares to current CGM offerings.

$199 keychain device available for patients with Apple iPhone and iPod Touch.

Plus, tips for traveling safely with diabetes.

Kelly’s take on connecting through technology at AADE15.

Hello there from San Francisco! I wanted to weigh in, so to speak, on Adam Brown’s valuable column this month . His in-depth inquiry shows what a “low-carb” and “non-low...

Why it may suggest shifting attitudes towards body image – and not in a good way.

Comment by March 26 to ensure that diabetes devices easily communicate with one another, other devices, and software.

Medicare Advantage pilot study shows average of 8.7% weight loss after six months.

The story of one boy’s struggle with stigma.

Practical advice for eating and drinking to combat childhood obesity.

TZD drug pioglitazone becomes second-ever diabetes drug to reduce heart disease and first to reduce strokes. Who might this benefit most?

Thoughts on democratizing health care, precision medicine, and more from Stanford MedX 2015.

Two new large studies investigate Finerenone in type 2 diabetes.

Plus, a massive $2 billion investment in new production facilities!

What I learned from doubling my carb intake: more work, more danger, but the same average blood sugar. Huh?